Litigation Details for Zogenix, Inc. v. Apotex Inc. (D. Del. 2021)

Zogenix, Inc. v. Apotex Inc. (D. Del. 2021)

Docket	1:21-cv-01252	Date Filed	2021-08-30
Court	District Court, D. Delaware	Date Terminated	2023-11-28
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	Defendant	Referred To
Parties	ZOGENIX INTERNATIONAL LTD.
Patents	10,452,815; 10,478,441; 10,478,442; 10,603,290; 10,947,183; 10,950,331; 11,406,606
Attorneys	Denise Seastone Kraft
Firms	Barnard, Mezzanotte, Pinnie, Seelaus & Kraft, LLP
Link to Docket	External link to docket

Details for Zogenix, Inc. v. Apotex Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-08-30				External link to document

Zogenix, Inc. v. Apotex Inc. | 1:21-cv-01252: Litigation Analysis

Last updated: February 19, 2026

This report analyzes the patent litigation between Zogenix, Inc. and Apotex Inc. concerning Zogenix's drug product, Fintepla (fenfluramine oral solution). The core of the dispute involves allegations of patent infringement and challenges to patent validity. Apotex seeks to market a generic version of Fintepla, initiating the legal proceedings.

What is the Basis of the Litigation?

The litigation centers on Zogenix's U.S. Patent No. 10,703,778 (the '778 patent). Zogenix alleges that Apotex's proposed generic product infringes claims 1, 6, 8, 9, 10, 11, 12, 13, 14, 15, 17, and 18 of this patent. Apotex, in turn, has filed counterclaims challenging the validity of the '778 patent, asserting that it is invalid and unenforceable.

What Patents Are Involved?

The primary patent at issue is U.S. Patent No. 10,703,778. This patent is listed in the U.S. Food and Drug Administration's (FDA) Orange Book for Fintegra. The '778 patent, titled "Methods for treating seizures," was issued on July 7, 2020. It claims methods of treating certain types of seizures in patients with Lennox-Gastaut syndrome (LGS) or Dravet syndrome using fenfluramine.

Apotex's ANDA (Abbreviated New Drug Application) for its generic fenfluramine oral solution product is seeking to market the drug for the same indications as Fintegra.

What are the Key Legal Arguments?

Zogenix's central argument is that Apotex's proposed generic product directly infringes upon the claims of the '778 patent. Zogenix contends that the administration of fenfluramine oral solution by Apotex for the treatment of LGS and Dravet syndrome falls within the scope of the patent's claims.

Apotex's defense strategy primarily involves challenging the validity of the '778 patent. Apotex asserts several grounds for invalidity, including:

• Obviousness: Apotex argues that the claimed invention would have been obvious to a person of ordinary skill in the art at the time the patent application was filed, based on prior art references.
• Lack of Enablement: Apotex may contend that the patent specification does not adequately describe how to make and use the claimed invention, thus failing to meet the enablement requirement of patent law.
• Indefiniteness: Apotex might argue that certain claims in the patent are not clear or precise enough to inform a person skilled in the art about the scope of the invention.
• Prior Art: Apotex is likely to present prior art that it believes anticipates the claims or renders them obvious.

What is the Procedural History of the Case?

The litigation commenced on June 11, 2021, when Zogenix filed its complaint against Apotex. This filing initiated the patent infringement lawsuit in the United States District Court for the District of Delaware. Apotex subsequently filed its Answer and Counterclaims on August 11, 2021, outlining its defenses and challenging the validity of the '778 patent.

Key procedural milestones include:

• Complaint Filing: June 11, 2021
• Answer and Counterclaims: August 11, 2021
• Discovery: Ongoing throughout the litigation, involving document production, interrogatories, and depositions.
• Claim Construction (Markman Hearing): This hearing is crucial for defining the meaning and scope of the patent claims. The court's claim construction order will significantly impact the infringement and validity analyses.
• Potential Settlement Discussions: Parties may engage in settlement negotiations at various stages.
• Summary Judgment Motions: Parties may file motions for summary judgment on certain issues, seeking to resolve them without a full trial.
• Trial: If no settlement is reached and no dispositive motions are granted, the case will proceed to trial.

What is the Status of the Litigation?

As of the latest available information, the litigation is active and proceeding through the discovery phase. A Markman hearing for claim construction has been scheduled. The outcome of this hearing will be a significant determinant of the litigation's trajectory.

What are the Potential Outcomes?

The potential outcomes of this litigation include:

• Zogenix Prevails: If the court finds that Apotex infringes the '778 patent and that the patent is valid, Apotex will be barred from launching its generic product during the patent's term. This would allow Zogenix to maintain market exclusivity for Fintegra.
• Apotex Prevails: If the court finds that Apotex does not infringe the '778 patent, or if the court invalidates the patent, Apotex may be permitted to launch its generic product.
• Partial Judgment: It is possible that the court could find infringement of some claims but not others, or find certain claims invalid and others valid, leading to a mixed outcome.
• Settlement: The parties may reach a settlement agreement, which could involve licensing terms, a delayed generic launch, or other mutually agreed-upon conditions.

What are the Commercial Implications?

The outcome of this litigation has significant commercial implications for both Zogenix and the pharmaceutical market:

For Zogenix:

• Market Exclusivity: A favorable ruling preserving the validity and enforceability of the '778 patent would protect Zogenix's market exclusivity for Fintegra, allowing it to continue to generate revenue from sales without generic competition.
• Revenue Protection: Fintegra is Zogenix's lead product. Protecting its market exclusivity is crucial for the company's financial stability and future R&D investments.
• Valuation Impact: The outcome of this litigation will directly influence Zogenix's market valuation and investor confidence.

For Apotex:

• Market Entry: A successful challenge to the '778 patent would enable Apotex to launch its generic fenfluramine oral solution, capturing a share of the market and generating revenue.
• Generic Drug Pricing: The entry of a generic competitor would likely lead to a significant decrease in the price of fenfluramine oral solution, benefiting patients and healthcare systems.
• Strategic Expansion: Successful generic launches are critical for Apotex's business strategy and its role as a provider of affordable medications.

For the Market:

• Access to Generics: The litigation's outcome will determine when patients gain access to a potentially lower-cost generic alternative for LGS and Dravet syndrome treatments.
• Precedent for Other Litigations: The court's rulings, particularly on claim construction and patent validity, could set precedents relevant to other pharmaceutical patent disputes.

Key Takeaways

• Zogenix, Inc. is defending its U.S. Patent No. 10,703,778 against infringement claims brought by Apotex Inc., which seeks to market a generic version of Fintegra (fenfluramine oral solution).
• Apotex is challenging the validity of the '778 patent on grounds including obviousness and enablement.
• The litigation is currently in the discovery phase, with a Markman hearing for claim construction scheduled.
• A favorable outcome for Zogenix would preserve market exclusivity for Fintegra, while a successful challenge by Apotex would permit generic entry and price reduction.
• The commercial implications are substantial, affecting Zogenix's revenue, Apotex's market entry, and patient access to affordable medication.

FAQs

1. What is the specific indication for Fintegra that is at the center of this patent dispute? The patent litigation concerns Fintegra's use in treating seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome.

2. Has the court issued any decisions regarding the validity of the '778 patent? As of the latest available information, no final decisions have been made regarding the patent's validity. The case is ongoing, and validity challenges are part of Apotex's defense strategy.

3. What is the significance of the Markman hearing in this litigation? The Markman hearing is crucial because the court will interpret the meaning and scope of the patent claims. This claim construction will then be used to determine whether Apotex's product infringes Zogenix's patent and can inform the validity analysis.

4. Are there any other generic manufacturers challenging Zogenix's patents for Fintegra? This report focuses specifically on the litigation between Zogenix, Inc. and Apotex Inc. (1:21-cv-01252). Information on other potential or ongoing litigation involving different generic manufacturers is not covered herein.

5. What is the expected timeline for the resolution of this litigation? Patent litigation can be lengthy and complex. While a Markman hearing is scheduled, the full resolution, including potential appeals, could extend for several years. Specific timelines depend on court schedules, the parties' actions, and the complexity of the legal and technical issues.

Citations

[1] Zogenix, Inc. v. Apotex Inc., No. 1:21-cv-01252 (D. Del. June 11, 2021).